Cagri + Sema (Cagrisema, Cagrilintide + Semaglutide Blend)
⚠️ Disclaimer: For Research Use Only. Not for human administration or clinical therapy.
Cagri+Sema = Cagrilintide + Semaglutide, commonly named Cagrisema, multi-receptor agonist peptide blend. Two separate peptides mixed as lyophilized powder, not a single fused molecule.
Individual Components Specs
1. Semaglutide
- CAS: 910463-68-2
- Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
- MW: 4113.58 g/mol
2. Cagrilintide
- CAS: 2415862-83-2
- Sequence: Ac-[MeLeu¹⁰, His¹¹, Glu¹⁶, desPro³⁷]-amylin analog, 37 amino acid peptide, C-terminal amide
- MW: 3990.46 g/mol
Blend Info
- Appearance: White to off-white lyophilized powder
- Typical research formulation ratio: Cagrilintide : Semaglutide = 1:1 molar / weight ratio (customizable)
- Solubility: Soluble in weak acidic aqueous buffer
- Storage: Lyophilized powder stored at -20℃, protected from light and moisture. Avoid repeated freeze-thaw cycles. After reconstitution, refrigerate and use promptly.
Development Background
Cagrisema combines two distinct peptide agonists:
- Semaglutide: GLP-1 receptor agonist, long-acting, DPP4 resistant.
- Cagrilintide: Amylin receptor agonist (calcitonin receptor/RAMP complex). The combination is studied for synergistic metabolic effects, originally from Novo Nordisk clinical research programs.
Mechanism of Action (Research Findings)
- Semaglutide (GLP-1 agonist): Glucose-dependent insulin release, suppress glucagon, slow gastric emptying, reduce appetite via hypothalamic GLP-1R.
- Cagrilintide (Amylin agonist): Further slows gastric emptying, inhibits postprandial glucagon, enhances satiety.
- Synergy: Dual receptor activation produces stronger reduction in food intake and body weight compared to single agent in preclinical metabolic models.
- Combined modulation of glucose homeostasis, energy expenditure and appetite signaling.
Research Areas
- Obesity & weight loss animal models
- Type 2 diabetes, glycemic control
- GLP‑1 / amylin receptor dual signaling
- Appetite, satiety and food intake research
- Pharmacodynamic synergy of peptide co-administration








评价
目前还没有评价